Press Release

March 17, 2022
1 min read

Jardiance phase 3 trial shows efficacy in patients with CKD, trial will stop early


Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The EMPA-Kidney trial will stop early due to evidence of Jardiance’s positive efficacy among patients with chronic kidney disease, according to a press release.

As the largest current SGLT2 inhibitor trial in CKD, EMPA-Kidney examined kidney disease progression and cardiovascular death in more than 6,000 adults with CKD when treated with Jardiance (empagliflozin). The early end of the trial comes from a recommendation by the trial’s independent data monitoring committee based on a formal interim assessment measuring positive efficacy.

people as kidneys
Source: Adobe Stock

"We are thrilled that the trial has shown that empagliflozin is beneficial among the patients studied in EMPA-Kidney," Richard Haynes, co-principal investigator, said in the release. "We are grateful to all of the participants who have made this trial possible and look forward to sharing detailed trial results later this year."

According to the press release, detailed results are planned to be presented at a medical conference in 2022.